G O L D M A R K A D V I S E R S, I N C.
C O N S U L T A T I V E
I N V E S T M E N T
B A N K I N G
Clients
DELCATH SYSTEMS, INC.
Delcath Systems is a development stage company founded in 1988 for the purpose of developing and marketing a proprietary drug delivery system capable of introducing and removing high doses of chemotherapy agents to a diseased organ while greatly inhibiting their entry into the general circulation system. It is hoped that the procedure will result in a meaningful treatment for cancer. In November 1989, the company was granted an Investigational Device Exemption and an Investigational New Drug status for its products by the FDA. Delcath Systems is seeking to complete Phase III human clinicals in order to obtain FDA pre-market approval for the use of its delivery system using various chemotherapy agents to treat malignant melanoma that has spread to the liver.
​
Client contact:
M.S. Koly, Former CEO
​